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properties are dynamic in nature. Therapeutic agents 
inhibiting tumor cell reprogramming may have the potential 
to increase the effectiveness of radiotherapy. Moreover, 
monitoring of CSC-related biomarker before and during the 
course of radiotherapy may be able to predict therapy 
response and clinical outcome. 
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Purpose or Objective: This study analyzed whether short-
term death of patients with peripheral stage I NSCLC can be 
predicted reliably to select a sub-group of patients, which 
will not have a benefit from SBRT and which can be referred 
to wait and see. 
 
Material and Methods: 802 patients with early stage NSCLC 
treated with SBRT in 5 institutes for whom information on 
overall survival within the first six months after treatment 
was available were included in this analysis. The probability 
of dying within six months after treatment was modeled by 
multivariate logistic regression; this interval was chosen 
because death of early stage NSCLC is a rare event within six 
months after diagnosis. Model fitting was performed using the 
LASSO method which simultaneously serves to select the 
features most closely related to the outcome. The 
performance of the model that would be achieved on an 
independent dataset was estimated using double 10-fold 
cross validation (CV). Because with CV the estimation of test 
performance depends somewhat on the splitting of the data 
sets, double 10-fold CV was repeated 100 times, resulting in 
1000 models from which the variance in the performance 
measure could be obtained. The variables age, gender, ECOG 
status, operability, FEV1 and Charlson comorbidity index 
(CCI) where considered for model building. 
 
Results: Using different variable combinations for model 
building resulted in different sample sizes and model 
performances (Table 1). Common among all models was the 
identification of the CCI as the most frequently selected and 
thus most important variable predicting six-months death, 
with increasing values predicting higher probability of death. 
Gender was consistently the second-most frequently selected 
variable. Regressing on the individual components of the CCI 
with the LASSO method showed that presence of a second 
solid tumor was the most important predictor, followed by 
various forms of heart disease (Figure 1). Replacing the CCI 
by these individual components in model building confirmed 
the strong relation between the presence of a second tumor 
and early death, but led to a worse model performance than 
with the full CCI (Table 1). Overall the accuracy of all models 
predicting six-months death was poor with maximum 
AUC=0.62. 
 
 
 
Conclusion: General patient characteristics together with 
comorbidity data, especially the history of a previous 
malignancy, can predict early death, however, prediction 
accuracy is insufficient to select patients to wait and see 
instead of offering SBRT as a curative treatment. 
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Purpose or Objective: NRG/RTOG 0813 is a phase I/II study 
designed to determine the maximal tolerated dose (MTD) and 
efficacy of SBRT for NSCLC with centrally located tumors. We 
hereby report the primary endpoint of the phase I portion of 
the study. 
 
Material and Methods: Medically inoperable pts with biopsy 
proven, PET staged T1-2 (<5cm)N0M0 NSCLC and centrally 
located tumors (within or touching the zone of the proximal 
bronchial tree or adjacent to mediastinal or pericardial 
pleura) were successively accrued onto a dose-escalating 5 
fraction SBRT schedule ranging from 10-12 Gy/fraction 
delivered over 1.5-2 weeks. Dose-limiting toxicity (DLT) was 
defined as any grade 3 or worse toxicity (per CTCAE v.4) 
occurring within first year, possibly, probably, or definitely 
related to treatment from a pre-specified list of cardiac, 
esophageal, respiratory or neurological toxicities. Any 
potential DLT within the initial year post-SBRT could have led 
to dose reduction for subsequent patients accrued, using 
TITE-CRM (time-to-event continual reassessment method) 
statistical design. MTD was defined as SBRT dose associated 
with a 20% probability of DLT.  
 
Results: 120 pts were accrued Feb 2009 to Sept 2013 from 43 
participating centers. Numbers (n) accrued into each cohort, 
n eligible for analysis (20 pts were excluded as they did not 
receive protocol treatment (12) or were ineligible (8)), and n 
evaluable for DLT analyses (11 not evaluable, 10 of whom 
died in the first year without a DLT) are shown in the table. 
Pts were elderly (median age 72), slightly more females 
(57%), majority had performance status 0-1 (84%). Most 
cancers were T1 (65%) and squamous cell (45%). Median 
follow up was 26.6 months. There were 5 events that met the 
definition of DLTs; Table details the protocol pre-specified 
DLTs and the worst treatment-related AEs (ie occurring at 
any time). MTD is 12.0 Gy/fr; Bayesian-based probability of 
DLT on this arm was 7.2% (95% CI 2.8 -14.4%). The grade 5 
AEs occurred at a mean 13 mo postSBRT (range 5.5-14mo). 
 
 
 
Conclusion: The rates of toxicity pre-specified as DLT were 
relatively low. The highest dose level allowed by the protocol 
was reached, and associated with 7.2% rate of DLT. This 
phase I/II trial of SBRT provides data to inform patients of 
the potential toxicities with a 5 fraction SBRT schedule for 
centrally located NSCLC, but data on efficacy are still 
awaited. 
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Purpose or Objective: Patients with early stage non-small 
lung carcinoma (NSCLC) located centrally within the thorax 
present a therapeutic challenge with stereotactic body 
radiation therapy (SBRT). We compared outcomes of early 
stage NSCLC located in central and peripheral locations. 
 
Material and Methods: A total of 472 patients with early 
stage NSCLC were identified from a prospective IRB-approved 
thoracic SBRT registry. Tumors were classified as central if 
they were within 2 cm of the proximal bronchial tree or 
immediately adjacent to the mediastinal or pericardial 
pleura. Peripheral tumors were treated to 54 Gy in 3 
fractions, and central tumors to 50 or 55 Gy in 5 fractions. 
Patients were reviewed for overall survival (OS) calculated 
from completion of therapy and local failure (LF). The log-
rank test and Cox regression were used to identify factors 
predictive of OS and LF. 
 
Results: 127 patients had central tumors and 345 had 
peripheral tumors. Median follow-up was 30 months for living 
patients. For the entire cohort at 2 years, OS was 57% and LF 
was 10%. OS at 2 years was 50% for patients with central 
tumors and 60% for those with peripheral tumors (p=0.11). LF 
at 2 years was 19% for central lesions and 8% for peripheral 
lesions (p=0.08). On multivariate analysis, increasing tumor 
size (HR 1.21 per cm, 95% CI: 1.10-1.33, p<0.0001), 
increasing age-adjusted Charlson comorbidity score (HR 1.15 
per point, 95% CI: 1.09-1.20, p<0.0001), and worse KPS (HR 
10.1 per 10% loss, 95% CI: 10.1-10.2, p=0.0003), but not 
location predicted for worse OS. Only increasing tumor size 
(HR 1.37/cm, 95% CI: 1.06-1.78, p=0.02) predicted for LF on 
multivariate analysis. 
 
Conclusion: The use of five SBRT fractions of 10-11 Gy for 
central early stage NSCLC results in similar outcomes as 
peripheral early stage NSCLC treated in three SBRT fractions 
of 18 Gy. Larger tumors result in worse outcomes suggesting 
the need for additional treatment strategies. 
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Purpose or Objective: Pulmonary tumours are subject to 
respiratory motion which induces PET/MRI artefacts and 
imposes to use specific additional margins when treated by 
radiotherapy (RT). Gating techniques can solve these issues 
by stabilizing lung targets, and sustaining breath-holds in 
maximal inspiration (MI). However, these are limited by the 
patient’s capacity to hold his breath. The purpose of this 
work was to implement a new non-invasive respiratory 
assistance using high frequency percussive ventilation (HFPV -
Percussionaire®; Idaho, USA), and to report its first clinical 
use in maintaining breath holds long enough during chest 
imaging and complex RT treatments. 
 
Material and Methods: ethical committee approval was 
obtained to conduct a clinical study, after evaluating its 
